- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on HER2 Gene Mutation in India
Total 19 results
-
Postgraduate Institute of Medical Education and...RecruitingPortal Vein Thrombosis | Anticoagulants and Bleeding Disorders | Hepatic Vein Thromboses | Hepatic Venous Outflow Obstruction | Portal Hypertension, Noncirrhotic | Portal Vein Occlusion | Portal Vein Embolism | JAK2 Mutation | CALR Gene Mutation | Prothrombin G20210AIndia
-
Dr Rajendra A. BadweTata Memorial HospitalRecruitingHER2 Positive Breast Cancer | Carcinoma Breast Stage IIndia
-
Novartis PharmaceuticalsCompletedNALP3 MutationUnited Kingdom, France, Germany, India, Spain
-
Tata Memorial HospitalRecruitingNon-small Cell Lung Cancer | Oligometastatic Disease | Driver MutationIndia
-
Postgraduate Institute of Medical Education and...RecruitingIntrahepatic Cholestasis of Pregnancy | Genetic Mutation | Health Related Quality of LifeIndia
-
Tata Memorial HospitalRecruitingAsymptomatic Brain Metastases | Driver Mutation Positive Non-small Cell Lung CancerIndia
-
Sun Pharma Advanced Research Company LimitedTerminatedAdvanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerUnited States, India
-
Hoffmann-La RocheCompletedHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast CancerIndia
-
CelltrionNippon Kayaku Co., Ltd.CompletedHER2-positive Carcinoma of BreastItaly, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Portugal, Spain, Taiwan, Costa Rica, New Zealand, Poland, Chile, Colombia, Guatemala, Israel, Hungary, India, Thailand
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
BiocadCompletedHuman Epithelial Receptor (HER)-2 Positive Breast CancerUkraine, Russian Federation, Belarus, India
-
Enzyvant Therapeutics GmBHCompletedFarber Disease | Farber's Disease | Farber Lipogranulomatosis | Acid Ceramidase Deficiency | Ceramidase Deficiency | N-Laurylsphingosine Deacylase Deficiency | ASAH1 MutationUnited States, Egypt, Canada, Italy, Turkey, Argentina, Germany, India, Sweden
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands